ImmuPharma Secures Shareholder Backing and Funding to Drive P140 and Kapiglucagon Programs

ImmuPharma ( (GB:IMM) ) has shared an update.

ImmuPharma has secured strong shareholder backing for its latest fundraising, with more than 88% support for resolutions enabling a £6 million Lanstead subscription and a £468,000 WRAP retail offering. The company says the new capital significantly reinforces its balance sheet and will underpin its strategic focus on advancing its P140 autoimmune platform and its Kapiglucagon program for type 1 diabetes.

Management is prioritising a value-enhancing partnering deal for P140 this year, citing recent patent progress, new supporting study data and a forthcoming scientific manuscript as strengthening the asset’s commercial appeal. The funding package, structured to share in potential future share price upside, is expected to extend ImmuPharma’s cash runway to at least the second half of 2028, giving it greater leverage in licensing talks and scope to accelerate Kapiglucagon and selectively invest in earlier-stage pipeline projects.

The company has launched an accelerated two-year development plan for Kapiglucagon, backed by the newly approved financing and accompanied by plans for regular progress updates as the asset advances towards potential partnering. The board says these steps set up 2026 as a year of delivery and momentum, with operational milestones in P140 and Kapiglucagon viewed as key drivers of potential value creation for shareholders.

The most recent analyst rating on (GB:IMM) stock is a Sell with a £6.00 price target. To see the full list of analyst forecasts on ImmuPharma stock, see the GB:IMM Stock Forecast page.

Spark’s Take on IMM Stock

According to Spark, TipRanks’ AI Analyst, IMM is a Neutral.

The score is weighed down primarily by very weak financial performance (near-zero revenue, persistent losses, ongoing cash burn, and negative equity). Technicals are mixed but modestly supportive versus the 200-day average, while valuation remains challenged due to losses and the absence of dividend yield.

To see Spark’s full report on IMM stock, click here.

More about ImmuPharma

ImmuPharma PLC is a specialist drug discovery and development company listed on the London Stock Exchange. The company focuses on autoimmune and metabolic diseases, with its lead technology platform P140 targeting autoimmune conditions and Kapiglucagon being developed as a treatment for type 1 diabetes, positioning ImmuPharma in niche, high-value therapeutic markets.

Average Trading Volume: 3,102,480

Technical Sentiment Signal: Sell

Current Market Cap: £22.82M

For a thorough assessment of IMM stock, go to TipRanks’ Stock Analysis page.